GlaxoSmithKline PLC has agreed to pay more than $150 million to settle fraud allegations over the pricing and marketing of two anti-nausea drugs, the Justice Department said Tuesday.

The pharmaceutical maker engaged in a scheme to inflate the price of Zofran and Kytril for the federal Medicare and Medicaid programs, which reimburse health care providers based on the manufacturers’ prices, the government said. The drugs are used mainly to counter nausea brought on by chemotherapy and radiation.